Azim Surka, MD
Pulmonary Disease · Greenville, SCNPI 1073626073
Payments from drug & device makers
Across 112 payments — averaging $68.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Noah Medical Corporation$1K
- Medical Device Business Services, Inc.$904
- Pulmonx Corporation$323
- Galvanize Therapeutics, Inc$318
- GSK$312
- plus $2K from 24 others
What the payments were for
- Travel & lodging$3,11141%
- Food & beverage$4,51259%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 19 | $3,096 |
| Noah Medical Corporation | 6 | $1,075 |
| Medical Device Business Services, Inc. | 7 | $904 |
| Pulmonx Corporation | 3 | $323 |
| Galvanize Therapeutics, Inc | 2 | $318 |
| GSK | 15 | $312 |
| Medtronic | 3 | $236 |
| AstraZeneca | 7 | $205 |
| Inari Medical, Inc. | 1 | $199 |
| Boehringer Ingelheim | 6 | $166 |
| Vapotherm Inc | 2 | $155 |
| Sunovion Pharmaceuticals Inc. | 9 | $141 |
| Abiomed | 2 | $87 |
| Insmed, Inc. | 3 | $52 |
| Mylan Specialty L.p. | 3 | $50 |
| Circassia Inc. | 3 | $42 |
| Genentech USA, Inc. | 3 | $40 |
| Philips North America LLC | 2 | $30 |
| Novartis | 2 | $30 |
| Sanofi | 2 | $27 |
| Resmed Corp | 2 | $25 |
| Electromed, Inc. | 2 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| United Therapeutics Corporation | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Bayer | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$2,905
- GALAXY$948
- MONARCH$829
- ALIYA SYSTEM$318
- FLOWTRIEVER CATHETER, S$199
- CT THROMBECTOMY SYSTEM KIT$199
- ILLUMISITE$161
- VAPOTHERM$150
- Pulmonx Endobronchial Valve EBV$135
- CHARTIS CATHETER$131
- ZEPHYR DELIVERY CATHETER$131
- ZEPHYR ENDOBRONCHIAL VALVE$131
- PULMONX CHARTIS TABLET CONSOLE$131
- TEZSPIRE$122
- NUCALA$115
How this compares
$7,657 in reported general payments places this provider in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $282,746 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 257 | $217,790 |
| NucalaMepolizumab | 28 | $116,057 |
| Dupixent PenDupilumab | 21 | $75,862 |
| XolairOmalizumab | 13 | $60,494 |
| Spiriva RespimatTiotropium Bromide | 85 | $53,996 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $49,236 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $41,508 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $31,648 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $17,932 |
| Arnuity ElliptaFluticasone Furoate | 48 | $14,695 |
| Qvar RedihalerBeclomethasone Dipropionate | 36 | $12,996 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $6,804 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $5,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $5,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $312 | $434,301507 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $166 | $378,249194 claims |
| AstraZenecaSymbicort | $205 | $17,93265 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Greenville
- Sean CallahanGreenville$501K
- Adam SchertzGreenville$54K
- Daniel Lo VerdeGreenville$14K
- Michael KasterGreenville$13K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.